secwatch.observer — SEC 8-K summary
======================================

Issuer:     Context Therapeutics Inc. (CNTX)
CIK:        0001842952
Form:       8-K
Filed at:   2023-03-22T23:59:59+00:00
Accession:  0001842952-23-000040
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 2.05, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Context Therapeutics discontinues ONA-XR, prioritizes CTIM-76; 2022 net loss $14.8M
--------------------------------------------------------------------------------

- Discontinued ONA-XR due to elevated LFTs in 3 patients and competitive landscape; exploring strategic options.
- Focusing on CTIM-76 (CLDN6 x CD3 bispecific) for solid tumors; IND expected Q1 2024.
- Cash $35.5M at Dec 31, 2022, down from $49.7M; cash runway extended into late 2024.
- 2022 net loss $14.8M vs $10.5M in 2021; R&D $7.1M, G&A $7.8M.
- CTIM-76 preclinical data at AACR April 17, 2023; investor R&D webinar same day.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842952/000184295223000040/0001842952-23-000040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842952/000184295223000040/cntx-20230317.htm
  HTML page:      https://secwatch.observer/filing/0001842952-23-000040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer